Evidence map›Paper›PMID 32278781›Full record

Trial reportChest2020

Effect of Venlafaxine on Apnea-Hypopnea Index in Patients With Sleep Apnea: A Randomized, Double-Blind Crossover Study.

Christopher N Schmickl, Yanru Li, Jeremy E Orr, Rachel Jen, Scott A Sands, Bradley A Edwards, Pamela DeYoung, Robert L Owens, Atul Malhotra

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Chest, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02714400 (The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02714400 phase4completednot on this map

The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea

TypeinterventionalSponsorUniversity of California, San DiegoRan2016 to 2016Enrolled20ConditionsObstructive Sleep ApneaArmsVenlafaxine, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double-blind, placebo-controlled, randomized crossover trial.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023
    Trial
  3. Trial
  4. The ventilatory response to arousal from sleep is elevated in young individuals with post-traumatic stress disorder symptoms.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Article
  5. Review
  6. [Current Status of and Progress in Research on Obstructive Sleep Apnea and Comorbid Depressive Disorders].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Christopher N SchmicklDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.
Yanru LiDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA; Department of Otorhinolaryngology Head and Neck Surgery, Sleep Medicine Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Electronic address: liyanruru@aliyun.com.
Jeremy E OrrDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.
Rachel JenDivision of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Scott A SandsDivision of Sleep and Circadian Disorders, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Bradley A EdwardsSleep and Circadian Medicine Laboratory, Department of Physiology, School of Biomedical Sciences and Biomedical Discovery Institute, Monash University, Melbourne, VIC, Australia; Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.
Pamela DeYoungDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.
Robert L OwensDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.
Atul MalhotraDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, San Diego, CA.
University of California System · USBeijing Tongren Hospital · CNBrigham and Women's Hospital · USMonash University · AUUniversity of British Columbia · CA

Funding

Is Obstructive Sleep Apnea Important in the Development of Alzheimer's DiseaseR01AG063925 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2020 to 2024
$3.7M
Single Motor Unit Genioglossus Recordings to Understand Sleep Apnea PathogenesisR01HL085188 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2008 to 2018
$3.5M
Underlying mechanisms of obesity-induced obstructive sleep apneaR01HL148436 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Atul Malhotra · 2020 to 2026
$3.4M
Training in the Next Generation in Respiratory ScienceT32HL134632 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL, POWELL, FRANK L. · 2017 to 2021
$2.1M
Assessment of Upper Airway Mechanics Using Newer Electromyographic TechniquesK24HL132105 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2016 to 2020
$611k
NHLBI NIH HHS K24 HL132105NHLBI NIH HHS R01 HL085188NHLBI NIH HHS R01 HL148436NHLBI NIH HHS T32 HL134632NIA NIH HHS R01 AG063925
6 · The paper itself

Abstract

backgroundOne of the key mechanisms underlying OSA is reduced pharyngeal muscle tone during sleep. Data suggest that pharmacologic augmentation of central serotonergic/adrenergic tone increases pharyngeal muscle tone. RESEARCH QUESTION: We hypothesized that venlafaxine, a serotonin-norepinephrine reuptake inhibitor, would improve OSA severity. STUDY DESIGN AND

methodsIn this mechanistic, randomized, double-blind, placebo-controlled crossover trial, 20 patients with OSA underwent two overnight polysomnograms ≥ 4 days apart, receiving either 50 mg of immediate-release venlafaxine or placebo before bedtime. Primary outcomes were the apnea-hypopnea index (AHI) and peripheral oxygen saturation (Spo

resultsOverall, there was no significant difference between venlafaxine and placebo regarding AHI (mean reduction, -5.6 events/h [95% CI, -12.0 to 0.9]; P = .09) or Spo

interpretationIn unselected patients, venlafaxine simultaneously worsened and improved various pathophysiologic traits, resulting in a zero net effect. Careful patient selection based on pathophysiologic traits, or combination therapy with drugs countering its alerting effects, may produce a more robust response. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02714400; URL: www.clinicaltrials.gov.

Indexed as

AdultCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedPharyngeal MusclesPolysomnographySerotonin and Noradrenaline Reuptake InhibitorsSeverity of Illness IndexSleep Apnea, ObstructiveVenlafaxine HydrochlorideSerotonin and Noradrenaline Reuptake InhibitorsVenlafaxine HydrochloridelungOSApharmacotherapypharyngeal muscle tonevenlafaxine

Identifiers

PMID32278781
PMCPMC7417375
OpenAlexW3015546993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.